Currently, to enroll participants into pharmaceutical trials strenuous and costly procedures are applied to test whether participants meet inclusion criteria or not; this includes travel to clinics, costly brain imaging, invasive assessments, or costly f2f assessments with experts. Moreover, screening for such inclusion criteria in clinical trials has significant fail rates and significant resources have to be spent on participant screening to enroll only a fraction of them (10%). Standard cognitive assessment typically uses a set of speech-based cognitive tests which have the potential to be conducted remotely in telecommunication settings. However, only recently speech analysis and automatic speech recognition, as well as semantic speech processing have become mature enough to automate such speech-based testing procedures. The European DeepSpA project aims to replace in-person manual pre-screening procedures by remote (semi-)automated analyses methods detecting relevant phenotype for novel Alzheimer trials automatically. To evaluate the feasibility of the phone-based solution in a real-world scenarioand examine the predictive potential for prognostic diagnosis, information extracted over the phone from the participant's speech in cognitive and narrative speech tasks will be analyzed for its usefulness for remote pre-screening. 120 participants at preclinical stages of cognitive impairment will be recruited from the local memory clinic. At baseline, a complete dataset (including speech recordings) will be collected, consisting of clinical data and biobank materials, e.g. blood samples, MRI and cerebrospinal fluid. After 6 months the participants will be called for a brief remote follow up evaluation on the phone consisting of a short interview on subjective cognitive decline, a verbal memory task, and fluency tasks in which speech features will be collected through a semi-automatic phone-based interface. Final data sets will be compared to each other. We expect to obtain comparable results between the telecommunication administration method and the traditional application. First preliminary results as well as a working demo version will be presented at the preconference. Built on existing speech technologies, we expect this first-of-its-kind service to allow to remotely conduct neurocognitive testing thus pre-screening of potential trial participants. This will significantly reduce the overall costs associated with the screening and speed up the trials' preparatory activities.